<p>Certara（纳斯达克代码：CERT - 获取免费报告）在周六发布给客户和投资者的研究报告中，被华尔街 Zen 的股票分析师将评级从 “持有” 上调至 “买入”。</p>
<ul>
<li>3 只可能在市场波动后飙升的动量股</li>
</ul>
<p>其他一些券商也对 CERT 发表了看法。KeyCorp 将 Certara 的目标价从 13.00 美元下调至 12.00 美元，并在 1 月 8 日的报告中对该股票给予 “增持” 评级。Stephens 将 Certara 的目标价从 15.00 美元下调至 12.00 美元，并在 12 月 12 日的研究报告中对该股票给予 “增持” 评级。Leerink Partners 将 Certara 的评级从 “市场表现” 上调至 “跑赢大盘”，并在 1 月 6 日的研究报告中为该公司设定了 13.00 美元的目标价。摩根士丹利将 Certara 的目标价从 16.00 美元下调至 12.00 美元，并在 12 月 18 日的报告中对该股票给予 “持平” 评级。最后，巴克莱将 Certara 的目标价从 14.00 美元下调至 13.00 美元，并在 12 月 15 日的研究报告中对该公司给予 “增持” 评级。一位股票研究分析师对该股票给予了强烈买入评级，七位给予了买入评级，六位给予了持有评级，一位给予了卖出评级。根据 MarketBeat.com 的数据，该股票目前的平均评级为 “适度买入”，共识目标价为 12.82 美元。</p>
<p><strong>阅读我们关于 Certara 的最新报告</strong></p>
<h2>Certara 价格表现</h2>
<ul>
<li>尽管每股收益超出预期，Simulations Plus 股票下跌 15%</li>
</ul>
<p>CERT 股票在周五开盘价为 7.23 美元。该公司的 50 日移动平均线为 9.06 美元，200 日移动平均线为 10.28 美元。公司的债务与股本比率为 0.27，流动比率为 2.09，速动比率为 2.09。该公司的市值为 11.5 亿美元，市盈率为 103.29，贝塔值为 1.47。Certara 的 1 年最低价为 7.16 美元，1 年最高价为 15.69 美元。</p>
<p>Certara（纳斯达克代码：CERT - 获取免费报告）最后一次公布季度财报是在 11 月 6 日。该公司报告季度每股收益为 0.14 美元，超出分析师一致预期的 0.11 美元，超出幅度为 0.03 美元。该季度的营业收入为 1.0462 亿美元，而一致预期为 1.0453 亿美元。Certara 的股本回报率为 5.18%，净利润率为 2.62%。在去年同期，该公司每股收益为 0.13 美元。分析师预计 Certara 在当前财政年度的每股收益将达到 0.28 美元。</p>
<h2>机构资金流入和流出</h2>
<ul>
<li>这 3 只小型动量股是否正在酝酿大幅上涨？</li>
</ul>
<p>机构投资者最近买入和卖出了该公司的股票。First Horizon Corp 在第三季度收购了 Certara 的新股份，价值约 30,000 美元。Versant Capital Management Inc 在第三季度将其在 Certara 的持仓提高了 66.7%。Versant Capital Management Inc 现在拥有 2,881 股该公司的股票，价值 35,000 美元，此前在此期间又收购了 1,153 股。Osaic Holdings Inc.在第二季度将其在 Certara 的持仓提高了 50.7%。Osaic Holdings Inc.现在拥有 3,491 股该公司的股票，价值 41,000 美元，此前在此期间又收购了 1,175 股。Elevation Point Wealth Partners LLC 在第二季度购买了 Certara 的新股份，价值约 59,000 美元。最后，Global Retirement Partners LLC 在第三季度将其在 Certara 的持仓增加了 45.0%。Global Retirement Partners LLC 现在拥有 5,636 股该公司的股票，价值 69,000 美元，此前在此期间又购买了 1,749 股。当前 73.96% 的股票由机构投资者和对冲基金持有。</p>
<h2>Certara 公司简介</h2>
<p>（获取免费报告）</p>
<p>Certara 是一家生物模拟软件和服务公司，与制药、生物技术和医疗器械开发商合作，加速药物发现、开发和监管审批。该公司的平台整合了定量药理学、真实世界证据、人工智能和机器学习，以模拟和模拟药物在多种治疗领域和患者群体中的行为。通过应用这些机制和数据驱动的方法，Certara 帮助客户预测临床结果，优化给药策略，并在产品生命周期内简化决策过程。</p>
<p>该公司的产品分为软件工具和咨询服务。</p>
<h2>了解更多</h2>
<ul>
<li>我们更看好的五只股票比 Certara 更好</li>
<li>新法律：国会批准数字美元的设立？</li>
<li>黄金市场崩溃的那一天</li>
<li>一位前 CIA 特工对即将到来的崩溃的看法</li>
<li>你的银行账户不再安全</li>
<li>他刚刚准确预测了另一个黄金走势……</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q0VSVA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="650" height="330" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q0VSVA"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Certara 吗？</h2>
<p>在考虑 Certara 之前，你会想听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而 Certara 并不在名单上。</p>
<p>虽然 Certara 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

CERT

<p>华尔街禅将 Certara（NASDAQ:CERT）的评级从 “持有” 上调至 “买入”。其他券商也调整了他们的目标价，KeyCorp 将其下调至 12.00 美元，Stephens 也下调至 12.00 美元，而 Leerink Partners 则设定为 13.00 美元。Certara 的股票开盘价为 7.23 美元，市值为 11.5 亿美元，市盈率为 103.29。该公司报告上个季度每股收益为 0.14 美元，超出预期。机构投资者持有该股票的 73.96%，该公司专注于药物开发的生物仿真软件</p>

<p>Certara (NASDAQ:CERT - Get Free Report) was upgraded by stock analysts at Wall Street Zen from a &#34;hold&#34; rating to a &#34;buy&#34; rating in a research report issued to clients and investors on Saturday.</p>
<div class="lb-trans"><p>Certara（纳斯达克代码：CERT - 获取免费报告）在周六发布给客户和投资者的研究报告中，被华尔街 Zen 的股票分析师将评级从 “持有” 上调至 “买入”。</p>
</div><ul>
<li>3 Momentum Stocks That Could Soar Post-Market Volatility</li>
</ul>
<div class="lb-trans"><ul>
<li>3 只可能在市场波动后飙升的动量股</li>
</ul>
</div><p>A number of other brokerages have also weighed in on CERT. KeyCorp reduced their price objective on shares of Certara from $13.00 to $12.00 and set an &#34;overweight&#34; rating on the stock in a report on Thursday, January 8th. Stephens cut their price target on Certara from $15.00 to $12.00 and set an &#34;overweight&#34; rating on the stock in a research note on Friday, December 12th. Leerink Partners raised Certara from a &#34;market perform&#34; rating to an &#34;outperform&#34; rating and set a $13.00 price objective for the company in a research report on Tuesday, January 6th. Morgan Stanley dropped their price objective on Certara from $16.00 to $12.00 and set an &#34;equal weight&#34; rating on the stock in a report on Thursday, December 18th. Finally, Barclays decreased their target price on Certara from $14.00 to $13.00 and set an &#34;overweight&#34; rating for the company in a research note on Monday, December 15th. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of &#34;Moderate Buy&#34; and a consensus target price of $12.82.</p>
<div class="lb-trans"><p>其他一些券商也对 CERT 发表了看法。KeyCorp 将 Certara 的目标价从 13.00 美元下调至 12.00 美元，并在 1 月 8 日的报告中对该股票给予 “增持” 评级。Stephens 将 Certara 的目标价从 15.00 美元下调至 12.00 美元，并在 12 月 12 日的研究报告中对该股票给予 “增持” 评级。Leerink Partners 将 Certara 的评级从 “市场表现” 上调至 “跑赢大盘”，并在 1 月 6 日的研究报告中为该公司设定了 13.00 美元的目标价。摩根士丹利将 Certara 的目标价从 16.00 美元下调至 12.00 美元，并在 12 月 18 日的报告中对该股票给予 “持平” 评级。最后，巴克莱将 Certara 的目标价从 14.00 美元下调至 13.00 美元，并在 12 月 15 日的研究报告中对该公司给予 “增持” 评级。一位股票研究分析师对该股票给予了强烈买入评级，七位给予了买入评级，六位给予了持有评级，一位给予了卖出评级。根据 MarketBeat.com 的数据，该股票目前的平均评级为 “适度买入”，共识目标价为 12.82 美元。</p>
</div><p><strong>Read Our Latest Report on Certara</strong></p>
<div class="lb-trans"><p><strong>阅读我们关于 Certara 的最新报告</strong></p>
</div><h2>Certara Price Performance</h2>
<div class="lb-trans"><h2>Certara 价格表现</h2>
</div><ul>
<li>Simulations Plus Stock Drops 15% Despite EPS Beat</li>
</ul>
<div class="lb-trans"><ul>
<li>尽管每股收益超出预期，Simulations Plus 股票下跌 15%</li>
</ul>
</div><p>CERT stock opened at $7.23 on Friday. The business's 50-day moving average is $9.06 and its two-hundred day moving average is $10.28. The company has a debt-to-equity ratio of 0.27, a current ratio of 2.09 and a quick ratio of 2.09. The firm has a market capitalization of $1.15 billion, a P/E ratio of 103.29 and a beta of 1.47. Certara has a 1 year low of $7.16 and a 1 year high of $15.69.</p>
<div class="lb-trans"><p>CERT 股票在周五开盘价为 7.23 美元。该公司的 50 日移动平均线为 9.06 美元，200 日移动平均线为 10.28 美元。公司的债务与股本比率为 0.27，流动比率为 2.09，速动比率为 2.09。该公司的市值为 11.5 亿美元，市盈率为 103.29，贝塔值为 1.47。Certara 的 1 年最低价为 7.16 美元，1 年最高价为 15.69 美元。</p>
</div><p>Certara (NASDAQ:CERT - Get Free Report) last announced its quarterly earnings data on Thursday, November 6th. The company reported $0.14 EPS for the quarter, topping analysts' consensus estimates of $0.11 by $0.03. The business had revenue of $104.62 million during the quarter, compared to the consensus estimate of $104.53 million. Certara had a return on equity of 5.18% and a net margin of 2.62%.During the same period in the previous year, the company posted $0.13 earnings per share. Analysts anticipate that Certara will post 0.28 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>Certara（纳斯达克代码：CERT - 获取免费报告）最后一次公布季度财报是在 11 月 6 日。该公司报告季度每股收益为 0.14 美元，超出分析师一致预期的 0.11 美元，超出幅度为 0.03 美元。该季度的营业收入为 1.0462 亿美元，而一致预期为 1.0453 亿美元。Certara 的股本回报率为 5.18%，净利润率为 2.62%。在去年同期，该公司每股收益为 0.13 美元。分析师预计 Certara 在当前财政年度的每股收益将达到 0.28 美元。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>机构资金流入和流出</h2>
</div><ul>
<li>Are These 3 Small Momentum Stocks Setting Up Big Gains?</li>
</ul>
<div class="lb-trans"><ul>
<li>这 3 只小型动量股是否正在酝酿大幅上涨？</li>
</ul>
</div><p>Institutional investors have recently bought and sold shares of the business. First Horizon Corp acquired a new stake in shares of Certara during the third quarter worth about $30,000. Versant Capital Management Inc lifted its position in Certara by 66.7% during the 3rd quarter. Versant Capital Management Inc now owns 2,881 shares of the company's stock worth $35,000 after acquiring an additional 1,153 shares during the period. Osaic Holdings Inc. lifted its position in Certara by 50.7% during the 2nd quarter. Osaic Holdings Inc. now owns 3,491 shares of the company's stock worth $41,000 after acquiring an additional 1,175 shares during the period. Elevation Point Wealth Partners LLC purchased a new position in shares of Certara in the 2nd quarter valued at approximately $59,000. Finally, Global Retirement Partners LLC increased its holdings in shares of Certara by 45.0% in the third quarter. Global Retirement Partners LLC now owns 5,636 shares of the company's stock valued at $69,000 after purchasing an additional 1,749 shares during the period. 73.96% of the stock is currently owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>机构投资者最近买入和卖出了该公司的股票。First Horizon Corp 在第三季度收购了 Certara 的新股份，价值约 30,000 美元。Versant Capital Management Inc 在第三季度将其在 Certara 的持仓提高了 66.7%。Versant Capital Management Inc 现在拥有 2,881 股该公司的股票，价值 35,000 美元，此前在此期间又收购了 1,153 股。Osaic Holdings Inc.在第二季度将其在 Certara 的持仓提高了 50.7%。Osaic Holdings Inc.现在拥有 3,491 股该公司的股票，价值 41,000 美元，此前在此期间又收购了 1,175 股。Elevation Point Wealth Partners LLC 在第二季度购买了 Certara 的新股份，价值约 59,000 美元。最后，Global Retirement Partners LLC 在第三季度将其在 Certara 的持仓增加了 45.0%。Global Retirement Partners LLC 现在拥有 5,636 股该公司的股票，价值 69,000 美元，此前在此期间又购买了 1,749 股。当前 73.96% 的股票由机构投资者和对冲基金持有。</p>
</div><h2>Certara Company Profile</h2>
<div class="lb-trans"><h2>Certara 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Certara is a biosimulation software and services company that partners with pharmaceutical, biotechnology and medical device developers to accelerate drug discovery, development and regulatory approval. The company's platform integrates quantitative pharmacology, real-world evidence, artificial intelligence and machine learning to model and simulate drug behavior across a range of therapeutic areas and patient populations. By applying these mechanistic and data-driven approaches, Certara helps its clients predict clinical outcomes, optimize dosing strategies and streamline decision-making throughout the product lifecycle.</p>
<div class="lb-trans"><p>Certara 是一家生物模拟软件和服务公司，与制药、生物技术和医疗器械开发商合作，加速药物发现、开发和监管审批。该公司的平台整合了定量药理学、真实世界证据、人工智能和机器学习，以模拟和模拟药物在多种治疗领域和患者群体中的行为。通过应用这些机制和数据驱动的方法，Certara 帮助客户预测临床结果，优化给药策略，并在产品生命周期内简化决策过程。</p>
</div><p>The company's offerings are divided into software tools and consulting services.</p>
<div class="lb-trans"><p>该公司的产品分为软件工具和咨询服务。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>了解更多</h2>
</div><ul>
<li>Five stocks we like better than Certara</li>
<li>NEW LAW: Congress Approves Setup For Digital Dollar?</li>
<li>The day the gold market broke</li>
<li>What a Former CIA Agent Knows About the Coming Collapse</li>
<li>Your Bank Account Is No Longer Safe</li>
<li>He just nailed another gold prediction …</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票比 Certara 更好</li>
<li>新法律：国会批准数字美元的设立？</li>
<li>黄金市场崩溃的那一天</li>
<li>一位前 CIA 特工对即将到来的崩溃的看法</li>
<li>你的银行账户不再安全</li>
<li>他刚刚准确预测了另一个黄金走势……</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q0VSVA" alt="" original-src="https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx?Prefix=NASDAQ&amp;Symbol=CERT"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Certara Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Certara 吗？</h2>
</div><p>Before you consider Certara, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Certara 之前，你会想听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Certara wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而 Certara 并不在名单上。</p>
</div><p>While Certara currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Certara 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Certara（纳斯达克股票代码：CERT）在 Wall Street Zen 被上调至买入评级